444 related articles for article (PubMed ID: 17336698)
1. Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency.
Chonchol M; Cook T; Kjekshus J; Pedersen TR; Lindenfeld J
Am J Kidney Dis; 2007 Mar; 49(3):373-82. PubMed ID: 17336698
[TBL] [Abstract][Full Text] [Related]
2. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
Tikkanen MJ; Holme I; Cater NB; Szarek M; Faergeman O; Kastelein JJ; Olsson AG; Larsen ML; Lindahl C; Pedersen TR;
Am J Cardiol; 2009 Mar; 103(5):577-82. PubMed ID: 19231315
[TBL] [Abstract][Full Text] [Related]
3. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
[TBL] [Abstract][Full Text] [Related]
4. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
J Am Coll Cardiol; 2008 Apr; 51(15):1448-54. PubMed ID: 18402899
[TBL] [Abstract][Full Text] [Related]
5. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
Hague W; Forder P; Simes J; Hunt D; Tonkin A;
Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
[TBL] [Abstract][Full Text] [Related]
6. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.
Rossebø AB; Pedersen TR; Boman K; Brudi P; Chambers JB; Egstrup K; Gerdts E; Gohlke-Bärwolf C; Holme I; Kesäniemi YA; Malbecq W; Nienaber CA; Ray S; Skjaerpe T; Wachtell K; Willenheimer R;
N Engl J Med; 2008 Sep; 359(13):1343-56. PubMed ID: 18765433
[TBL] [Abstract][Full Text] [Related]
7. The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials.
Holdaas H; Wanner C; Abletshauser C; Gimpelewicz C; Isaacsohn J
Int J Cardiol; 2007 Apr; 117(1):64-74. PubMed ID: 16889855
[TBL] [Abstract][Full Text] [Related]
8. Reduction of myocardial ischemia with simvastatin in addition to conventional treatment in patients with chronic coronary artery disease.
Verri V; Cunha AB; Tessarolo LE; Carneiro RC; Romêo Filho LJ
Rev Port Cardiol; 2004 Sep; 23(9):1089-105. PubMed ID: 15587571
[TBL] [Abstract][Full Text] [Related]
9. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Sever PS; Poulter NR; Dahlof B; Wedel H;
J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
[TBL] [Abstract][Full Text] [Related]
10. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS).
Yokoyama M; Origasa H;
Am Heart J; 2003 Oct; 146(4):613-20. PubMed ID: 14564313
[TBL] [Abstract][Full Text] [Related]
11. Renal dysfunction in acute stroke: an independent predictor of long-term all combined vascular events and overall mortality.
Tsagalis G; Akrivos T; Alevizaki M; Manios E; Stamatellopoulos K; Laggouranis A; Vemmos KN
Nephrol Dial Transplant; 2009 Jan; 24(1):194-200. PubMed ID: 18728156
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
[TBL] [Abstract][Full Text] [Related]
13. Effect of pravastatin on cardiovascular events in people with chronic kidney disease.
Tonelli M; Isles C; Curhan GC; Tonkin A; Pfeffer MA; Shepherd J; Sacks FM; Furberg C; Cobbe SM; Simes J; Craven T; West M
Circulation; 2004 Sep; 110(12):1557-63. PubMed ID: 15364796
[TBL] [Abstract][Full Text] [Related]
14. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment.
Wilhelmsen L; Pyörälä K; Wedel H; Cook T; Pedersen T; Kjekshus J
Eur Heart J; 2001 Jul; 22(13):1119-27. PubMed ID: 11428852
[TBL] [Abstract][Full Text] [Related]
16. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S).
Strandberg TE; Pyörälä K; Cook TJ; Wilhelmsen L; Faergeman O; Thorgeirsson G; Pedersen TR; Kjekshus J;
Lancet; 2004 Aug 28-Sep 3; 364(9436):771-7. PubMed ID: 15337403
[TBL] [Abstract][Full Text] [Related]
17. Effect of xuezhikang on cardiovascular events and mortality in elderly patients with a history of myocardial infarction: a subgroup analysis of elderly subjects from the China Coronary Secondary Prevention Study.
Ye P; Lu ZL; Du BM; Chen Z; Wu YF; Yu XH; Zhao YC;
J Am Geriatr Soc; 2007 Jul; 55(7):1015-22. PubMed ID: 17608873
[TBL] [Abstract][Full Text] [Related]
18. [Treatment with hydroxymethylglutaryl coenzyme-A-reductase inhibitors in elderly patients: is it necessary?].
Alexa ID; Panaghiu L; Ungureanu G
Rev Med Chir Soc Med Nat Iasi; 2005; 109(4):721-6. PubMed ID: 16610166
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
Silva M; Matthews ML; Jarvis C; Nolan NM; Belliveau P; Malloy M; Gandhi P
Clin Ther; 2007 Feb; 29(2):253-60. PubMed ID: 17472818
[TBL] [Abstract][Full Text] [Related]
20. Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS.
Ray KK; Bach RG; Cannon CP; Cairns R; Kirtane AJ; Wiviott SD; McCabe CH; Braunwald E; Gibson CM;
Eur Heart J; 2006 Oct; 27(19):2310-6. PubMed ID: 16887854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]